Meta-analysis
Open access
First‐Line PD‐1 Inhibitor‐Based Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Revised Systematic Review and Meta‐Analysis of Phase III Trials
V. Rothweiler
C. Roderburg
M. Koeksal
B. Jensen
Torsten Feldt
I. Gencer
Johannes C. Fischer
W. Budach
W. Knoefel
G. Lu
E. Boelke
Medicine
Abstract
Immune checkpoint blockade has changed the first‐line treatment landscape for advanced esophageal squamous cell carcinoma (ESCC), but the magnitude and consistency of benefit across phase III trials require careful synthesis.